Date published: 2025-10-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

DD3 Inhibitors

DD3 inhibitors represent a class of chemical compounds specifically designed to target and inhibit the activity of the enzyme DD3, which plays a significant role in various biochemical pathways. The DD3 enzyme is a highly conserved protein involved in intricate cellular processes, including signal transduction, metabolic regulation, and protein modification. Its structure, typically characterized by a unique active site with a highly selective binding pocket, allows for the precise modulation of substrate processing. DD3 inhibitors function by binding to this active site, thereby preventing the enzyme from interacting with its natural substrates. This inhibition can lead to a cascade of downstream effects, altering various metabolic and signaling pathways within the cell. The design and development of DD3 inhibitors require an in-depth understanding of the enzyme's three-dimensional structure, often achieved through techniques such as X-ray crystallography or NMR spectroscopy. This structural knowledge enables chemists to design inhibitors that fit precisely within the enzyme's active site, ensuring maximum efficacy and selectivity. In addition to their role in modulating DD3 enzyme activity, these inhibitors are also of particular interest in chemical biology for their potential to elucidate the enzyme's broader role in cellular functions. By selectively inhibiting DD3, researchers can study the effects of its inhibition on various cellular processes, gaining insights into the enzyme's physiological roles. The specificity of DD3 inhibitors is often enhanced through structural optimization, which may involve modifying functional groups to improve binding affinity or alter the inhibitor's pharmacokinetic properties. Furthermore, the synthesis of these inhibitors typically involves a combination of synthetic organic chemistry and structure-based drug design, with iterative cycles of synthesis and biological evaluation to refine their inhibitory properties. As a result, DD3 inhibitors not only serve as valuable tools in basic biochemical research but also contribute to a deeper understanding of the enzyme's role in complex biological systems.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Flufenamic acid

530-78-9sc-205699
sc-205699A
sc-205699B
sc-205699C
10 g
50 g
100 g
250 g
$26.00
$77.00
$151.00
$303.00
1
(1)

Flufenamic acid, a nonsteroidal anti-inflammatory drug, can inhibit AKR1C1 by competing for the enzyme's binding sites, preventing the reduction of steroids and other substrates, thus indirectly suppressing the enzyme's activity in steroid metabolism.

Indomethacin

53-86-1sc-200503
sc-200503A
1 g
5 g
$28.00
$37.00
18
(1)

Indomethacin acts as an inhibitor of prostaglandin synthesis enzymes and can indirectly inhibit AKR1C1 by altering prostaglandin levels, which may affect the enzyme's substrate specificity or availability, leading to reduced activity.

Nonoxynol, n=9

26027-38-3sc-204821
sc-204821A
50 g
100 g
$92.00
$157.00
(2)

Nonoxynol, n=9 is a surfactant used as a spermicide, can disrupt cellular membranes and potentially alter AKR1C1′s cellular environment, indirectly inhibiting its activity by affecting enzyme stability or cofactor availability.

Mefenamic acid

61-68-7sc-205380
sc-205380A
25 g
100 g
$104.00
$204.00
6
(0)

Mefenamic acid, another NSAID, can inhibit AKR1C1 by competing with substrates for binding to the enzyme, thereby reducing its ability to convert steroids and potentially affecting steroid hormone regulation.

Ketoconazole

65277-42-1sc-200496
sc-200496A
50 mg
500 mg
$62.00
$260.00
21
(1)

Ketoconazole, an antifungal agent, inhibits cytochrome P450 enzymes and can indirectly affect AKR1C1 activity by altering steroid biosynthesis upstream, thus impacting substrate availability for AKR1C1.

Anastrozole

120511-73-1sc-217647
10 mg
$90.00
1
(1)

Anastrozole, an aromatase inhibitor, reduces estrogen synthesis and can indirectly inhibit AKR1C1 by decreasing the availability of estrogenic substrates, impacting the enzyme's role in estrogen metabolism.

Trilostane

13647-35-3sc-208469
sc-208469A
10 mg
100 mg
$224.00
$1193.00
2
(1)

Trilostane inhibits 3β-hydroxysteroid dehydrogenase, indirectly affecting AKR1C1 by altering the pool of steroid substrates available for reduction, potentially reducing the enzyme's activity in steroid metabolism.

Finasteride

98319-26-7sc-203954
50 mg
$103.00
3
(1)

Finasteride, a 5α-reductase inhibitor, can indirectly inhibit AKR1C1 by reducing the production of dihydrotestosterone, thus affecting the balance of steroid substrates that AKR1C1 may act upon.

Letrozole

112809-51-5sc-204791
sc-204791A
25 mg
50 mg
$85.00
$144.00
5
(1)

Letrozole, another aromatase inhibitor, reduces estrogen levels and indirectly inhibits AKR1C1 by limiting the availability of estrogenic substrates, impacting the enzyme's metabolic activity.

Sulindac

38194-50-2sc-202823
sc-202823A
sc-202823B
1 g
5 g
10 g
$31.00
$84.00
$147.00
3
(1)

Sulindac, by inhibiting cyclooxygenase, indirectly affects AKR1C1 activity by modifying prostaglandin synthesis, which could influence the enzyme's regulation or substrate specificity.